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a  b  s  t  r  a  c  t
Background:  For  regulatory  approval,  consistency  in manufacturing  of  vaccine  lots  is  expected  to  be
demonstrated  in  conﬁrmatory  immunogenicity  studies  using  two-sided  equivalence  trials.  This  ran-
domized,  double-blind  study  (NCT01323972)  assessed  consistency  of  three  RTS,S/AS01  malaria  vaccine
batches  formulated  from  commercial-scale  puriﬁed  antigen  bulk lots  in  terms  of  anti-CS-responses
induced.
Methods:  Healthy  children  aged  5–17 months  were  randomized  (1:1:1:1)  to  receive  RTS,S/AS01  at  0-
1-2  months  from  one  of three  commercial-scale  puriﬁed  antigen  bulk  lots  (1600  litres-fermentation
scale;  commercial-scale  lots),  or a  comparator  vaccine  batch  made  from  pilot-scale  puriﬁed  antigen  bulk
lot  (20  litres-fermentation  scale;  pilot-scale  lot).  The  co-primary  objectives  were  to  ﬁrst  demonstrate
consistency  of  antibody  responses  against  circumsporozoite  (CS)  protein  at one  month  post-dose  3  for  the
three  commercial-scale  lots  and  second  demonstrate  non-inferiority  of anti-CS  antibody  responses  at  one
month  post-dose  3 for  the commercial-scale  lots  compared  to the  pilot-scale  lot. Safety  and reactogenicity
were  evaluated  as  secondary  endpoints.
Results: One  month  post-dose-3,  anti-CS  antibody  geometric  mean  titres (GMT)  for  the 3 commercial
scale  lots  were  319.6  EU/ml  (95%  conﬁdence  interval  (CI):  268.9–379.8),  241.4  EU/ml  (207.6–280.7),  and
302.3  EU/ml  (259.4–352.3).  Consistency  for the  RTS,S/AS01  commercial-scale  lots  was demonstrated  as
the  two-sided  95% CI of  the anti-CS  antibody  GMT  ratio  between  each  pair  of lots  was  within  the range
of  0.5–2.0.  GMT  of the  pooled  commercial-scale  lots  (285.8  EU/ml  (260.7–313.3))  was  non-inferior  to  the
pilot-scale  lot  (271.7  EU/ml  (228.5–323.1)).  Each  RTS,S/AS01  lot  had  an  acceptable  tolerability  proﬁle,
with  infrequent  reports  of grade  3 solicited  symptoms.  No  safety  signals  were  identiﬁed  and no  serious
adverse  events  were  considered  related  to vaccination.
Conclusions: RTS,S/AS01  lots  formulated  from commercial-scale  puriﬁed  antigen  bulk  batches  induced
a  consistent  anti-CS  antibody  response,  and  the  anti-CS  GMT  of  pooled  commercial-scale  lots  was  non-
inferior  to  that  of a lot  formulated  from  a  pilot-scale  antigen  bulk  batch.©  2014  The  Authors.  Publis
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1. Introduction
The RTS,S/AS01 candidate malaria vaccine targets the Plasmo-
dium falciparum circumsporozoite (CS) protein, therefore acting at
the pre-erythrocytic stage of the parasite life cycle [1]. This is a
partially efﬁcacious vaccine, which has shown protection against
both clinical and severe malaria in young children and infants in a
large phase 3 trial in Africa [2,3], and has an acceptable safety pro-
ﬁle when co-administered with vaccines included in the routine
Expanded Programme on Immunization [2–4].
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For regulatory approval of a new vaccine, it is necessary to
emonstrate the quality of the manufacturing process, including
onsistency in the manufacturing of vaccine lots [5–7]. The assess-
ent is expected to be performed in conﬁrmatory immunogenicity
tudies using two-sided equivalence trials [8,9]. This study eval-
ated the consistency and safety of three different RTS,S/AS01
accine lots formulated from commercial-scale puriﬁed antigen
ulk lots. The co-primary objectives were to demonstrate lot-to-lot
onsistency in terms of anti-CS antibody responses and, if reached,
ubsequently to demonstrate non-inferiority of the commercial-
cale lots to a RTS,S/AS01 vaccine lot derived from pilot-scale
uriﬁed antigen bulk material.
. Methods
.1. Study design and ethics
This  was a phase III, randomized, double-blind study (Clinical-
rials.gov, NCT01323972) conducted at two sites between May
011 and May  2012: University of Nigeria Teaching Hospital in
nugu, which is located in south-east Nigeria, and Jos University
eaching Hospital in Jos, which is in north-central Nigeria.
The  production scale of the RTS,S puriﬁed bulk antigen was
ncreased from 20 litres-fermentation (pilot-plant scale, produced
n January 2010; hereafter referred to as pilot-scale lot) to 1600
itres-fermentation (commercial-scale scale in commercial facili-
ies, produced in October/November 2010; hereafter referred to
s commercial-scale lots). The same starting material was  used at
oth manufacturing scales, and the components of the ﬁnal vac-
ine, including the adjuvant system, remained identical. Eligible
hildren were randomized (1:1:1:1) to receive one of three dif-
erent commercial-scale lots (lot 1, 2 or 3) or the pilot-scale lot
comparator) of RTS,S/AS01 vaccine according to a 0, 1 and 2 month
chedule.
A randomization list was generated by the study sponsor via
n internet-based system, and treatment allocation at each site
as performed using MATEX, a program developed for Statistical
nalysis System (SAS®; Cary, NC, USA).
The study protocol was approved by the ethics review commit-
ee of each study site and by the National Agency for Food and
rug Administration and Control in Nigeria and Western Institu-
ional Review Board in the USA. Overall, this study was  conducted in
ccordance with Good Clinical Practice guidelines and all applicable
egulatory requirements, including the Declaration of Helsinki. The
rial was conducted in partnership with the PATH Malaria Vaccine
nitiative. An Independent Data Monitoring Committee oversaw
he study’s progress and safety of the children, assisted by a local
afety monitor (an experienced physician) at each site.
.2.  Study population
Healthy  children aged 5–17 months at the time of ﬁrst vac-
ination were eligible for enrolment. As phase II evaluation of
TS,S/AS01 indicated that previous hepatitis B immunization may
nﬂuence RTS,S-induced antibody responses in children [10], to be
ligible for participation, all participants must have received three
oses of hepatitis B vaccine before the study start. Exclusion criteria
ncluded a history of an immunodeﬁcient or neurological condi-
ion, acute disease or fever (axillary temperature ≥37.5 ◦C) at the
ime of enrolment, and an acute or chronic, clinically signiﬁcant
ulmonary, cardiovascular, hepatic or renal functional abnormal-
ty. Chronic administration of immune-modifying drugs was  not
ermitted. Unapproved use of a drug or vaccine within 30 days
efore the ﬁrst study vaccine dose and administration of a licensed
accine within 7 days of the ﬁrst dose were also exclusion criteria. (2014) 6556–6562 6557
Written  informed consent was  obtained from the children’s parents
or guardians. Illiterate parents indicated consent with a thumbprint
and a signature was obtained from an independent literate witness.
2.3. Study vaccine
Each  vaccine dose contained lyophilized RTS,S (25 g) reconsti-
tuted with 500 l of AS01E (referred to elsewhere in this paper as
AS01), a liposome-based Adjuvant System containing monophos-
phoryl lipid A (MPL) and Quillaja saponaria Molina, fraction 21
(QS21, Antigenics Inc., a wholly owned subsidiary of Agenus Inc.,
Lexington, Massachusetts, USA). The vaccines were administered
intramuscularly to the deltoid muscle of the left arm and vaccine
recipients were observed for at least 60 min following each vac-
cination with appropriate medical treatment available in case of
anaphylactic shock.
2.4.  Study objectives
The  co-primary objectives of the study were to ﬁrst demon-
strate consistency of anti-CS antibody responses at one month
post-dose 3 for three commercial-scale RTS,S/AS01 lots. If the ﬁrst
primary objective was met, then the second primary objective was
to demonstrate non-inferiority of anti-CS antibody responses at one
month post-dose 3 of the RTS,S/AS01 commercial-scale lots com-
pared to the pilot-scale lot. The safety and reactogenicity of the
vaccine lots were evaluated as secondary endpoints.
2.5. Immunogenicity assessment
Assessment  of anti-CS and anti-hepatitis B surface antigen (anti-
HBs) antibody titres were performed at the Centre for Vaccinology,
Ghent University, Belgium, on serum samples taken before dose 1
and one month after dose 3. Antibodies against CS were measured
by evaluating immunoglobulin (Ig) G responses to the CS-repeat
region, using a validated enzyme-linked immunosorbent assay
(ELISA) with R32LR as the capture antigen and a threshold for a
positive titre of 0.5 EU/ml [11]. Anti-HBs antibodies were measured
using an in-house sandwich ELISA. The cut-off for seroprotection
was 10 mIU/ml [12].
2.6. Safety and reactogenicity assessments
Solicited local (injection site pain, redness and swelling) and
general (drowsiness, irritability, loss of appetite and fever) adverse
events (AEs) were recorded during the 7-day follow-up, and unso-
licited AEs during the 30-day follow-up, after each vaccine dose.
Serious AEs (SAEs) were reported throughout the study. Grade 3
(severe) solicited AEs were deﬁned as follows: pain causing cry-
ing when limb is moved/spontaneously painful, swelling or redness
>20 mm in diameter, drowsiness that prevented normal daily activ-
ity, irritability (crying that could not be comforted) that prevented
normal activity, loss of appetite (not eating at all), fever with axil-
lary temperature >39.0 ◦C, or any other AE that prevented normal
daily activity. All solicited local reactions were considered causally
related to vaccination; the relationship of other AEs was classiﬁed
as possible or not causally related. Fever (temperature >37.5 ◦C)
was evaluated for cause by study investigators.
2.7. Statistical analyses
Statistical  analyses were performed using SAS version 9.2 on
Windows and StatXact-8.1 procedure on SAS.
A sample size of 80 children per group was  planned to have at
least 70 evaluable children in each group (3 lots of commercial-
scale and 1 pilot-scale lot). This sample size had >90% power to
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Fig. 1. Study proﬁle. Footnote on the exclusion from ATP analyses: 7 subjects were excluded from the ATP analysis due to randomization failure: 5 subjects received 3
injections and were found at unblinding to have received vaccines from the wrong lot, and for 2 subjects one dose of the vaccine was switched due to an error in labelling at


























eiolated the weight-for-age Z-score criteria after recalculation by the GSK-statistici
arents  with the date-of-birth provided on the vaccination card; 3 subjects were va
each the primary endpoint of equivalence of anti-CS antibody
esponses one month post-dose 3 between the three commercial-
cale lots and, if reached, demonstrating non-inferiority of the
ooled commercial-scale lots versus the pilot-scale lot in terms of
nti-CS antibody response one month post-dose 3, using an alpha
evel of 5% (2-sided).
Immunogenicity analysis was performed on the according-
o-protocol (ATP) cohort for immunogenicity, i.e. those meeting
ll eligibility criteria, complying with the procedures deﬁned
n the protocol. Anti-CS and anti-HBs antibody geometric mean
itres (GMTs) were calculated with 95% conﬁdence intervals (CIs).
ercentages of subjects with seropositive levels of anti-CS antibod-
es (≥0.5 EU/ml) and seroprotective levels of anti-HBs antibodies
≥10 mIU/ml) were determined. Pairwise anti-CS antibody GMT
atios between the groups and their two-sided 95% CIs were com-
uted using an ANOVA model on the log10-transformed titre with
he vaccine group as ﬁxed effect. Lot-to-lot equivalence was con-
luded if all three 95% CIs on the GMT  ratios were within the
ange 0.5–2, ruling out a 2-fold increase/decrease between each
air of lots. Non-inferiority of the pooled commercial-scale lots was
emonstrated by evaluating the upper limit of the two-sided 95%
I of the GMT  ratio of comparator pilot-scale lot and the pooled
ommercial-scale lots. If the upper limit of the two-sided 95%
I was below 2, non-inferiority was concluded. The co-primary
ndpoints were reached if the three equivalence criteria and thed 1 subject was  too old for inclusion after comparing the date-of-birth provided by
ted outside the protocol-deﬁned interval for vaccination.
non-inferiority  criteria were reached, so no type 1 error rate adjust-
ment was  proposed; instead the type 2 error rate was adjusted to
have sufﬁcient overall power.
Safety analysis was  conducted on the total vaccinated cohort.
The percentage of doses followed by at least one solicited AE and




A  total of 320 children (80 per group) were randomized 1:1:1:1
to 3 treatment groups receiving three doses of RTS,S/AS01 vaccine
from one of three commercial-scale (1600L) lots or a comparator
group, which received the RTS,S/AS01 vaccine pilot-scale (20L) lot.
Despite best efforts to monitor the study as frequently as possible
during a period of civil unrest in Nigeria, there were deviations
which led to the exclusion of 27 of 316 subjects who  received all
3 injections from the ATP analyses. Reasons for not receiving three
vaccine doses and reasons for exclusion from the ATP cohort for
immunogenicity are shown in Fig. 1.
Three children were withdrawn from the study because of
migration from the study area, two  because of consent withdrawal
not due to an AE and three were lost to follow-up (Fig. 1). The
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Table  1
Demographic characteristics (ATP cohort for immunogenicity).
Commercial-scale
lot 1 (N = 72)
Commercial-scale
lot 2 (N = 72)
Commercial-scale
lot 3 (N = 73)
Pilot-scale lot
(comparator) (N = 72)
Mean age ± SD (months) 9.7 ± 3.2 10.2 ± 3.6 10.1 ± 3.2 10.2 ± 3.0
Mean  weight-for-age Z-score ± SD −0.7 ± 1.1 −0.8 ± 1.0 −0.6 ± 1.0 −0.8 ± 0.9
Gender  (%), female/male 55.6/44.4 54.2/45
SD, standard deviation; N, number of children.
Table 2
Assessment of consistency among three commercial-scale vaccine lots in terms
of anti-CS antibody geometric mean titre (GMT) ratios one month after the third
RTS,S/AS01 vaccine dose (ATP cohort for immunogenicity).
Ratio order N Anti-CS antibody GMT  ratio
Value 95% CIa
Commercial-scale Lot 1:Lot 2 72:72 1.32 1.06, 1.65
Commercial-scale Lot 1:Lot 3 72:73 1.06 0.85, 1.32


























N, number of children with available results.
a Equivalence was  concluded if all three 95% CIs on GMT  ratios were within the
ange  0.5–2, ruling out a 2-fold increase/decrease between each pair of lots.
emographic characteristics of the participants were consistent
mong groups in terms of mean age and mean weight-for-age Z-
core; some variability in gender ratios was observed (Table 1).
.2.  Immunogenicity
Consistent immune responses were demonstrated for the three
ommercial-scale lots of RTS,S/AS01: one month after the third vac-
ine dose, the two-sided 95% CI of the anti-CS antibody GMT  ratio
etween each pair of lots was within the range 0.5–2 (Table 2). Non-
nferiority of the pooled commercial-scale lots to the pilot-scale lot
as also demonstrated; the anti-CS antibody GMT  ratio, pilot-scale
ot: pooled commercial-scale lot, was 0.95 (95% CI: 0.79, 1.15). The
nti-CS antibody GMT  was 271.7 EU/ml (95% CI: 228.5, 323.1) for
he pilot-scale lot and 285.8 EU/ml (95% CI: 260.7, 313.3) for the
ooled commercial-scale lot (Table 3).
Before vaccination, anti-CS prevalence was below 3% in all
roups, with low titres in those who were positive (Table 3). One
onth after the third vaccine dose, all vaccine recipients in each
roup were seropositive for anti-CS antibodies (Fig. 2a), with anti-
S antibody GMTs ranging from 241.4 EU/ml (95% CI: 207.6, 280.7)
o 319.6 EU/ml (95% CI: 268.9, 379.8) (Table 3).
The  majority of children in each group (≥91.8%) had sero-
rotective anti-HBs antibody titres before vaccination reﬂecting
rior hepatitis B vaccination (Table 3). One month after the third
able 3
nti-CS antibody seropositivity and anti-HBs antibody seroprotective rates, and geome
ilot-scale lot (ATP cohort for immunogenicity).
Group Timing N Anti-CS titre, EU/ml (95
≥0.5, % children GM
Commercial-scale Lot 1 PRE 72 2.8 (0.3–9.7) 
Month  3 72 100 (95.0–100) 31
Commercial-scale Lot 2 PRE 72 0.0 (0.0–5.0) 
Month  3 72 100 (95.0–100) 24
Commercial-scale Lot 3 PRE 73 2.7 (0.3–9.5) 
Month  3 73 100 (95.1–100) 30
Pooled  commercial-scale Lots 1, 2, 3 PRE 217 1.8 (0.5–4.7) 
Month  3 217 100 (98.3–100) 28
Pilot-scale  (Comparator) Lot PRE 72 1.4 (0.0–7.5) 
Month  3 72 100 (95.0–100) 27
, number of children with available results; PRE, pre-vaccination; Month 3, one month a.8 42.5/57.5 36.1/63.9
vaccine  dose, all children in each group had seroprotective anti-HBs
antibody titres (Fig. 2b) and GMTs ranged from 46,384.7 to 74,105
(Table 3).
3.3.  Reactogenicity and safety
Overall per dose incidences of each solicited local and gen-
eral AE during the 7-day period after vaccination were comparable
among groups (Fig. 3). In each group, pain was  the most common
solicited local AE and fever was  the most common solicited gen-
eral AE (Fig. 3). There were ﬁve reports of grade 3 fever (>39.0 ◦C);
one following a commercial-scale lot 1 dose (incidence 0.4%; 95%
CI: 0.0–2.3) and four following commercial-scale lot 3 doses (1.7%;
95% CI: 0.5–4.3). There were no other reports of grade 3 solicited
local or general AEs.
During  the 30-day period after vaccination, at least one unso-
licited AE was reported in a similar proportion of children
in each group (77.8%, 75.9%, 87.5% and 72.5% of children in
commercial-scale lots 1, 2, 3 and the pilot-scale lot, respectively –
Supplementary Table 1); none were of grade 3 intensity and none
were considered causally related to vaccination. The most com-
monly reported unsolicited AEs were malaria (reported in 36, 35,
41 and 33 children in commercial-scale lots 1, 2, 3 and pilot-scale
lot, respectively) and respiratory tract infection (27, 23, 27 and 23,
respectively).
Thirteen SAEs were reported during the study in eight children
(three children in commercial-scale lot 1, two  in lot 2, one in lot
3 group and two  in the pilot-scale lot), including four reports of
severe/complicated malaria and three sepsis reports. None of the
SAEs were considered related to vaccination and all events resolved
during the study.
4.  DiscussionIn this phase III, randomized, double-blind study in young
Nigerian children, consistency of anti-CS antibody responses
was demonstrated for the three RTS,S/AS01 vaccine commercial-
scale lots. Furthermore, the anti-CS antibody response to
tric mean titres (GMTs) for commercial-scale lots 1, 2 and 3, and the comparator
% CI) Anti-HBs titre, mIU/ml (95% CI)
T  ≥10, % children GMT
0.3 (0.2–0.3) 95.8 (88.3–99.1) 352.8 (217.1–573.4)
9.6 (268.9–379.8) 100 (95.0–100) 54,250.2 (43,293.6–67,979.7)
0.3 (0.3–0.3) 94.4 (86.4–98.5) 202.3 (131.1–312.3)
1.4 (207.6–280.7) 100 (95.0–100) 46,067.3 (33,919.2–62,566.2)
0.3 (0.2–0.3) 91.8 (83.0–96.9) 293.7 (170.5–506.1)
2.3 (259.4–352.3) 100 (95.1–100) 67,384.7 (52,271.4–86,867.7)
0.3 (0.2–0.3) 94.0 (90.0–96.8) 275.8 (208.4–365.1)
5.8 (260.7–313.3) 100 (98.3–100) 55,273.5 (47,508.3–64,308.0)
0.3 (0.2–0.3) 95.8 (88.3–99.1) 313.7 (201.7–487.6)
1.7 (228.5–323.1) 100 (95.0–100) 74,105.0 (58,613.6–93,690.7)
fter third vaccine dose.
















rig. 2. Reverse cumulative distribution curve for anti-CS and anti-HBs antibody tit
ntibody titres. (B) Anti-HBs antibody titres.
ommercial-scale lots was non-inferior to the response to a
TS,S/AS01 pilot-scale lot.
The anti-CS antibody GMTs observed in this trial one month
fter the third dose were 286 EU/ml for the pooled commercial-
cale lots and 272 EU/ml for the pilot-scale lot. This was  lower than
bserved in other RTS,S/AS01 studies of children of the same age,
sing the same validated anti-CS assay [2,13]. The anti-CS antibody
MT in the phase 3 multicentre efﬁcacy trial was 621 EU/ml (95%
I: 592–652) in 5–17 month old children, but this pooled value
asked the substantial variation in anti-CS antibody GMTs by site
hich ranged from 348 to 787 EU/ml [14]. Despite this variation,
accine efﬁcacy was at least 40% for all sites in the phase 3 efﬁ-
acy trial, and no association was seen at site-level between GMTs
nd vaccine efﬁcacy. Further understanding of immunological cor-
elates of protection is expected to be generated from the phasee month after the third vaccine dose (ATP cohort for immunogenicity). (A) Anti-CS
3  multicentre RTS,S/AS01 efﬁcacy trial that is ongoing [15]. Vari-
ation in immune responses has been described for other vaccines
antigens [16] and is believed to have both host and environmental
origins [17,18]. Because we did not assess vaccine efﬁcacy, and in
the absence of a control (placebo or non-RTS,S vaccine), the clinical
relevance of this ﬁnding cannot be directly assessed in the current
trial.
Each RTS,S/AS01 lot had an acceptable tolerability proﬁle, which
was in line with observations in the large RTS,S/AS01 phase III trial
among children of a similar age [2]. In both studies, the most fre-
quently reported solicited symptoms were pain and fever and grade
3 symptoms occurred infrequently. No safety signals were identi-
ﬁed in the present study and none of the SAEs were considered
related to vaccination. The most frequently reported unsolicited
AEs were malaria, respiratory tract infections, diarrhoea, and
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iFig. 3. Frequency of solicited local and general adverse events (overall per d
astroenteritis in all groups. These are common in children of the
tudy age group (Malaria-055).
In  conclusion, these results conﬁrm that RTS,S/AS01 vaccines
ormulated from commercial-scale puriﬁed antigen bulk lots are
roduced consistently. Anti-CS antibody responses induced were
on-inferior to those induced by the batch made from pilot-scale
uriﬁed antigen bulk lot.
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